Clinical Trial

Effect of ZaStaprazan on Platelet Reactivity of Clopidogrel After PercuTaneous CoronAry InteRvention

Study acronym: EZ-STAR
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-25
Trial Details
NCT Number NCT07471867
Lead Sponsor Yonsei University
Collaborators: Jeil Pharmaceutical Co., Ltd.
Conditions Chronic Coronary Syndrome
Enrollment 100 participants
Start Date 2026-04-02
Primary Completion 2028-07-12 (estimated)
Study Completion 2028-07-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-24